Forward P/S Multiple: Integra LifeSciences Holdings Corporation (IART)
With premium pricing power in neurosurgery, Integra LifeSciences (IART) has temporarily faced regulatory constraints. The projected P/S multiple, where the metric level is 0.00, helps assess the chances of a price recovery. Stable cash flow is supported by consistent demand for consumables, while growth potential is based on the restart of capacities and strategic acquisitions.
Summary analytical data breakdowns for Integra LifeSciences Inc. (IART)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital Integra LifeSciences|IART - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Integra LifeSciences|IART - Company Aggregate Debts|Debt to Book Capitalization Ratio Integra LifeSciences Inc.|IART - Company Long-Term Debt|Company Current Liabilities Integra LifeSciences|Quick Ratio integralife.com
- financial results and valuation multiples details:
IART - Company Net Income|Expected Profit Integra LifeSciences|IART - Market Cap to Net Income Ratio|Projected Price to Earnings Integra|IART - PEG Multiple|EV/EBITDA Multiple Integra LifeSciences Inc.|IART - Operating income before deduction of amortization|Earnings per share for the last twelve months Integra LifeSciences|IART - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months integralife.com|IART - Net earnings per share growth this year|Earnings growth forecast for next year Integra LifeSciences
- sales and revenue indicators:
Fundamental company analysis:IART (Integra LifeSciences Holdings Corporation)
When screening for issuer reliability, it is critical to evaluate market value relative to expected sales. Forward P/S is calculated as the ratio of current market capitalization to projected revenue, eliminating the volatility of short-term quotes. For Integra LifeSciences (IART), this ratio reflects the market rate for synergies derived from the acquisition of biomaterial developers and neurosurgery partnerships. The trend of the forward P/S indicator on the GURU.Markets platform allows for the differentiation of real business growth from speculative liquidity inflows.
Who Integra LifeSciences competes with
Price-to-Projected Revenue Ratio Boston Scientific Corporation BSX|EW - Forward Price-to-Revenue Multiple|ResMed Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Insulet Inc.|ZBH: Forward P/S Multiple|Market Cap to Projected Revenue COO|ALGN (Align Technology) - Forward P/S Multiple|Globus Medical Inc (GMED) - Market Cap to Expected Sales Ratio|Forward P/S Multiple TMDX|Forward Price-to-Revenue Multiple Alphatec Corp ATEC|Forward P/S Multiple AORT (Artivion, Inc.)|Forward P/S Multiple enovis.com ENOV|ESTA - Price-to-Projected Revenue Ratio|BBNX: Price-to-Projected Revenue Ratio|IRMD (Iradimed) - Forward Price-to-Revenue Multiple|Embecta Health - Forward Price to Sales|TNDM (Tandem Diabetes Care) - Forward P/S Multiple|Market Cap to Future Revenue Ratio axogeninc.com AXGN|Price-to-Projected Revenue Ratio SI-BONE (SIBN)|Orthofix Medical (OFIX) - Projected Price to Revenue|Bioventus Corp - Forward Price-to-Revenue Multiple|Forward P/S Multiple OrthoPediatrics Corp KIDS|Treace Medical Concepts - Forward P/S Multiple|Market Cap to Expected Sales Ratio blade.com SRTA|Carlsmed (CARL) - Price-to-Projected Revenue Ratio|Future Price to Revenue RXST (RxSight Inc)|Price-to-Projected Revenue Ratio ClearPoint Neuro Inc.|Forward Price-to-Revenue Multiple Stereotaxis Corporation (STXS)|Forward P/S Multiple STIM|SGHT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Orchestra BioMed, Inc. OBIO|ANIK: Market Cap to Projected Revenue|NSPR: Forward Price-to-Revenue Multiple|Jin Medical International - Price to Expected Revenue Ratio|VANI: Forward P/S Multiple|XTNT - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio NeuroOne Medical Technologies Corporation|Market Cap to Projected Revenue MODD (Modular Med)|Forward Price-to-Revenue Multiple MYO (Myomo, Inc)|Price to Expected Revenue Ratio COCH|Forward P/S Multiple VVOS (Vivos Therapeutics)|envveno.com (NVNO) - Market Cap to Future Revenue Ratio|SINTX Technologies - Forward P/S Multiple|Projected Price to Revenue Tenon Medical Inc. (TNON)|ReWalk Robotics Ltd (LFWD) - Price-to-Projected Revenue Ratio|Autonomix Medical - Forward Price to Sales|IVF (INVO Fertility Inc) - Forward P/S Multiple|Forward P/S Multiple bonebiologics.com|Forward Price-to-Revenue Multiple AXNX (Axonics)|BIOL (BIOLASE Inc.) - Forward Price to Sales|Price-to-Projected Revenue Ratio Dynatronics DYNT|Paragon 28 Inc. - Price-to-Projected Revenue Ratio|INVO Bio - Forward P/S Multiple
